These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 16260522)
1. Third-trimester maternal toxicity with nevirapine use in pregnancy. Joy S; Poi M; Hughes L; Brady MT; Koletar SL; Para MF; Fan-Havard P Obstet Gynecol; 2005 Nov; 106(5 Pt 1):1032-8. PubMed ID: 16260522 [TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864 [TBL] [Abstract][Full Text] [Related]
5. Adverse effects of antiretrovirals in HIV-infected pregnant women. Zuk DM; Hughes CA; Foisy MM; Robinson JL; Singh AE; Houston S Ann Pharmacother; 2009 Jun; 43(6):1028-35. PubMed ID: 19491318 [TBL] [Abstract][Full Text] [Related]
6. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy. Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E; Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530 [TBL] [Abstract][Full Text] [Related]
7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
8. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. João EC; Calvet GA; Menezes JA; D'Ippolito MM; Cruz ML; Salgado LA; Matos HJ Am J Obstet Gynecol; 2006 Jan; 194(1):199-202. PubMed ID: 16389032 [TBL] [Abstract][Full Text] [Related]
9. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Watts DH; Balasubramanian R; Maupin RT; Delke I; Dorenbaum A; Fiore S; Newell ML; Delfraissy JF; Gelber RD; Mofenson LM; Culnane M; Cunningham CK; Am J Obstet Gynecol; 2004 Feb; 190(2):506-16. PubMed ID: 14981398 [TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514 [TBL] [Abstract][Full Text] [Related]
11. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. Ena J; Leach A; Nguyen P HIV Med; 2008 Oct; 9(9):747-56. PubMed ID: 18651856 [TBL] [Abstract][Full Text] [Related]
12. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114 [TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979 [TBL] [Abstract][Full Text] [Related]
14. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551 [TBL] [Abstract][Full Text] [Related]
15. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. Kondo W; Carraro EA; Prandel E; Dias JM; Perini J; Macedo RL; Cornelsen TC; Sbalquiero R; Sasaki Md Braz J Infect Dis; 2007 Dec; 11(6):544-8. PubMed ID: 18327464 [TBL] [Abstract][Full Text] [Related]
16. Risk for immune-mediated liver reactions by nevirapine revisited. Medrano J; Barreiro P; Tuma P; Vispo E; Labarga P; Blanco F; Soriano V AIDS Rev; 2008; 10(2):110-5. PubMed ID: 18615121 [TBL] [Abstract][Full Text] [Related]
17. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. Duran AS; Losso MH; Salomón H; Harris DR; Pampuro S; Soto-Ramirez LE; Duarte G; de Souza RS; Read JS; AIDS; 2007 Jan; 21(2):199-205. PubMed ID: 17197811 [TBL] [Abstract][Full Text] [Related]
18. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. Martinson NA; Morris L; Johnson J; Gray GE; Pillay V; Ledwaba J; Dhlamini P; Cohen S; Puren A; Steyn J; Heneine W; McIntyre JA AIDS; 2009 Apr; 23(7):809-16. PubMed ID: 19287298 [TBL] [Abstract][Full Text] [Related]
19. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. Littera R; Carcassi C; Masala A; Piano P; Serra P; Ortu F; Corso N; Casula B; La Nasa G; Contu L; Manconi PE AIDS; 2006 Aug; 20(12):1621-6. PubMed ID: 16868443 [TBL] [Abstract][Full Text] [Related]